Paige Collaborates with Microsoft to Transform Cancer Diagnosis and Treatment with the Use of Pathology AI
Companies to lead digital transformation of pathology and cancer diagnosis NEW YORK–(BUSINESS WIRE)–Paige announced a…
Year: 2023
Quinbrook Expands Rowan Green Data Center Platform
Appoints Industry Veterans Bobby Hollis and Dan McNary to Senior Leadership Roles SAN FRANCISCO–(BUSINESS WIRE)–Quinbrook…
Built In Honors Iterative Health in Its Esteemed 2023 Best Places To Work Awards
The Cambridge-headquartered company earned a place on Built In’s Best Places to Work List for…
Built In Honors Vendr in Its Esteemed 2023 Best Places To Work Awards
Vendr Earns Boston Best Startups to Work For on Built In’s Best Places to Work…
Sensormatic Solutions by Johnson Controls to Showcase Digital Solutions Enabling the Future of Retail at NRF 2023
Sensormatic Solutions will be on site at the 2023 NRF Big Show to showcase the…
Pioneer of AI-Powered Image Analytics Software Drives 150% SaaS Sales Growth, Expands Global Customer Footprint and Makes Key Executive Addition
BOSTON–(BUSINESS WIRE)–Vizit, the leader in image analytics software for global brands and retailers, today announced…
Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF
MINNEAPOLIS, Jan. 11, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company…
Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Tuesday, January 17, 2023 at 1:00 PM ET PHILADELPHIA, PA and…
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development,…
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders…
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with…
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives
SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing…
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company…
Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity
Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1…
Genetic Technologies Provides Business Update
MELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a…
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
Innovation Passport provides entry to the U.K.’s Innovative Licensing and Access Pathway (ILAP), which aims…
Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2022
Fourth Quarter Net Revenue of $2.6 Million; Full-Year Net Revenue of $10.0 Million;Active Customer Sites…
Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab
Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial Solutions MORRISVILLE, N.C., Jan. 11,…
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX),…